TY - JOUR
T1 - Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma
AU - Runowicz, Carolyn D.
AU - Wadler, Scott
AU - Rodriguez-Rodriguez, Lorna
AU - Litwin, Peter
AU - Shaves, Mark
AU - O'Hanlan, Katherine A.
AU - Goldberg, Gary L.
AU - Tomainov, Catherine T.
AU - Byrnes, Richard
PY - 1989/9
Y1 - 1989/9
N2 - Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 × 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.
AB - Patients with locally advanced cervical cancer have a poor prognosis. The efficacy of radiotherapy is limited by the presence of large tumor volume and nodal disease. As cisplatin is a documented radiosensitizer and has activity in squamous cell carcinomas, a prospective study was designed to evaluate the toxicity and potential synergism of concurrent cisplatin (20 mg/m2 × 5 d every 21 days) and radiotherapy in locally advanced cervical cancer. Forty-three patients were studied, of which 14 were stage IB/IIA (bulky disease) and 29 were stage IIB/IIIB/IVA. Of the 32 evaluable patients, there were 29 complete responders. Of these 29 patients, 27 remain without evidence of disease, with a median follow-up of 12 months. There were no treatment-related deaths. Cisplatin and radiotherapy appear to be a well-tolerated and highly effective regimen for locally advanced cervical cancer.
UR - http://www.scopus.com/inward/record.url?scp=1342314123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1342314123&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(89)90180-7
DO - 10.1016/0090-8258(89)90180-7
M3 - Article
C2 - 2767531
AN - SCOPUS:1342314123
SN - 0090-8258
VL - 34
SP - 395
EP - 401
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -